Home » Stocks » PAVM

PAVmed Inc. (PAVM)

Stock Price: $5.93 USD 0.06 (1.02%)
Updated Jul 23, 2021 4:00 PM EDT - Market closed
Market Cap 497.34M
Revenue (ttm) n/a
Net Income (ttm) -29.52M
Shares Out 73.95M
EPS (ttm) -0.54
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 23
Last Price $5.93
Previous Close $5.87
Change ($) 0.06
Change (%) 1.02%
Day's Open 5.90
Day's Range 5.73 - 6.00
Day's Volume 1,081,917
52-Week Range 1.63 - 7.06

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

NEW YORK, June 14, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today anno...

1 month ago - GlobeNewsWire

NEW YORK, June 10, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced that its major ...

1 month ago - GlobeNewsWire

New subsidiary Veris acquires privately held oncology digital health company Oncodisc Inc.

1 month ago - GlobeNewsWire

NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, and its major subsidiary Lucid D...

1 month ago - GlobeNewsWire

NEW YORK, May 25, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced...

2 months ago - GlobeNewsWire

Initial NYU experience in 99 patients demonstrated EsoCheck and EsoGuard capable of detecting esophageal precancer in chronic heartburn patients

2 months ago - GlobeNewsWire

Conference call to be held today at 4 :30 P M E D T

2 months ago - GlobeNewsWire

Dr. David Poppers to present on his initial experience with Lucid's EsoCheck and EsoGuard

2 months ago - GlobeNewsWire

Four new senior executives will support growth strategy focused on multi-channel EsoGuard commercialization

2 months ago - GlobeNewsWire

Company conference call and webcast at 4:30 PM EDT

2 months ago - GlobeNewsWire

NEW YORK, April 29, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today announced that its m...

2 months ago - GlobeNewsWire

NEW YORK, April 27, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today ann...

2 months ago - GlobeNewsWire

Analysts say these penny stocks are a buy right now & have bullish price targets to boot. The post Penny Stocks To Buy According To Analysts With Price Targets Up to 341% appeared first on Penny Stocks ...

Other stocks mentioned: EVGN, SVRA, SYBX
3 months ago - PennyStocks

NEW YORK, April 15, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a commercial-stage, multi-product medical device company, today announced that Lishan Aklog, M...

3 months ago - GlobeNewsWire

NEW YORK, April 08, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today ann...

3 months ago - GlobeNewsWire

On-demand corporate presentation scheduled for March 17, 2021

4 months ago - GlobeNewsWire

NEW YORK, March 03, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announc...

4 months ago - GlobeNewsWire

NEW YORK, March 01, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today ann...

4 months ago - GlobeNewsWire

NEW YORK, Feb. 25, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announce...

5 months ago - GlobeNewsWire

NEW YORK, Feb. 23, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announce...

5 months ago - GlobeNewsWire

NEW YORK, Feb. 22, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announce...

5 months ago - GlobeNewsWire

Announces majority-owned subsidiary Lucid Diagnostics intends to spin-off into a separate public company

5 months ago - GlobeNewsWire

Conference call and live webcast was previously scheduled for 4:30 PM EST

5 months ago - GlobeNewsWire

NEW YORK, Feb. 16, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today anno...

5 months ago - GlobeNewsWire

NEW YORK, Feb. 09, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announce...

5 months ago - GlobeNewsWire

NEW YORK, Jan. 08, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announce...

6 months ago - GlobeNewsWire

NEW YORK, Jan. 06, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announce...

6 months ago - GlobeNewsWire

NEW YORK, Dec. 22, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announce...

7 months ago - GlobeNewsWire

NEW YORK, Dec. 18, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announce...

7 months ago - GlobeNewsWire

NEW YORK, Dec. 11, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announce...

7 months ago - GlobeNewsWire

PAVmed's (PAVM) CEO Lishan Aklog on Q3 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Conference call to be held today at 4:30 p.m. Eastern time

8 months ago - GlobeNewsWire

NEW YORK, Nov. 02, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announce...

8 months ago - GlobeNewsWire

The company has multiple promising medical devices in various states of regulatory approval, although three of these have already entered the commercial stage. Yet, like for most pre-revenue medical dev...

8 months ago - Seeking Alpha

NEW YORK, Sept. 08, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today annou...

10 months ago - GlobeNewsWire

PAVmed Inc. (PAVM) CEO Lishan Aklog on Q2 2020 Results and Business Update - Earnings Call Transcript

11 months ago - Seeking Alpha

Conference call to be held today at 4:30 p.m. Eastern time

11 months ago - GlobeNewsWire

NEW YORK, Aug. 06, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announ...

11 months ago - GlobeNewsWire

NEW YORK, July 28, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announ...

11 months ago - GlobeNewsWire

NEW YORK, July 13, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announ...

1 year ago - GlobeNewsWire

NEW YORK, June 17, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced the Company is ...

1 year ago - GlobeNewsWire

NEW YORK, June 15, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that medical di...

1 year ago - GlobeNewsWire

NEW YORK, June 11, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that its majori...

1 year ago - GlobeNewsWire

Executed LOI with Canon Virginia, Inc. to develop and implement commercial grade processes to manufacture molded resorbable pediatric ear tubes from aqueous silk fibroin

1 year ago - GlobeNewsWire

PAVMed Is About To Enter The Commercialization Phase

1 year ago - Seeking Alpha

PAVmed Inc. (PAVM) CEO Lishan Aklog on Q1 2020 Results and Business Update - Earnings Call Transcript

1 year ago - Seeking Alpha

Conference call to be held today at 4:30 p.m. Eastern time

1 year ago - GlobeNewsWire

PAVmed: Small Medical Device Maker With New FDA Approval And Multiple Catalysts

1 year ago - Seeking Alpha

NEW YORK, April 21, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced it has receive...

1 year ago - GlobeNewsWire

PAVmed Inc. (PAVM) CEO Lishan Aklog on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

About PAVM

PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE). Its product pipeline also comprises EsoGuard, a molecular diagnostic esophageal DNA test; EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo, a disposable infusi... [Read more...]

Industry
Medical Devices
IPO Date
Apr 28, 2016
Stock Exchange
NASDAQ
Ticker Symbol
PAVM
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for PAVmed stock is "Strong Buy." The 12-month stock price forecast is 8.63, which is an increase of 45.53% from the latest price.

Price Target
$8.63
(45.53% upside)
Analyst Consensus: Strong Buy